Advertisement

Aveo Pharmaceuticals Inc. has regained development and commercialization rights to AV-299, a drug target being tested to treat non-small cell lung cancer, from Merck subsidiary Schering Corp.

“The decision to return this program to AVEO is a result of portfolio prioritization,” said David Nicholson, Merck senior vice president and head of worldwide licensing and knowledge management, in a press release.

SOURCE

Advertisement
Advertisement